PROCEPT BioRobotics (PRCT) opened Q1 2026 with total revenue of US$83.1 million and a basic EPS loss of US$0.56, while trailing twelve month figures showed revenue of US$322.0 million and a basic EPS loss of US$1.83, keeping profitability firmly in focus for investors. Over recent quarters the company has seen revenue move from US$69.2 million in Q1 2025 to US$83.1 million in Q1 2026, alongside quarterly basic EPS losses ranging from US$0.35 to US$0.56, so the market is likely to zero in on how efficiently that top line is being converted given margins remain under pressure.

See our full analysis for PROCEPT BioRobotics.

With the headline numbers on the table, the next step is to set these results against the prevailing narratives around growth versus profitability to see which stories line up with the data and which ones get questioned.

Revenue Growth With TTM Above US$320 Million

• On a trailing twelve month basis, PROCEPT BioRobotics reported revenue of US$322.0 million compared with US$224.5 million two years earlier, while quarterly revenue over the last six periods has stayed in a band of roughly US$68.2 million to US$83.3 million.
• Supporters of the bullish view point to analyst expectations for about 23.9% to 26.5% annual revenue growth over the next three years, and Q1 2026 revenue of US$83.1 million sits above the US$69.2 million seen in Q1 2025. They argue that this backs the idea of solid top line momentum, although the trailing twelve month revenue figure of US$322.0 million still coincides with a trailing twelve month net loss of US$102.5 million, so the revenue story has not yet translated into profitability.

Bulls argue that this combination of a growing revenue base and expanding adoption of Aquablation and HYDROS systems could support long term upside if operating leverage eventually improves. However, the current loss profile means that view rests heavily on future execution rather than current earnings power. 🐂 PROCEPT BioRobotics Bull Case

Losses Over US$100 Million Keep Profit In Focus

• Trailing twelve month net income excluding extra items stands at a loss of US$102.5 million, with quarterly net losses ranging from US$18.9 million to US$31.6 million across the last six reported quarters, and basic EPS losses running between US$0.35 and US$0.56 per quarter.
• Critics who lean toward the bearish narrative highlight that losses have widened at about 10.2% per year over the past five years and forecasts suggest the company is unlikely to reach profitability in the next three years. They see the combination of a trailing twelve month EPS loss of US$1.83 and ongoing quarterly losses of around US$20 million to US$30 million as evidence that operating expenses and cost of goods remain a headwind even as revenue scales.

Skeptics also point to the risk section of the bearish narrative, which flags ongoing high spending on R&D and commercialization plus supply chain and reimbursement pressures. They argue that with no clear forecasted break into positive earnings the current loss level leaves little room for disappointment if growth slows. 🐻 PROCEPT BioRobotics Bear Case

P/S Of 4.2x Sits Between Industry And Peers

• The shares trade on a P/S of 4.2x compared with 2.8x for the broader US Medical Equipment industry and 5.2x for the peer group, so the stock is priced at a premium to the wider industry but at a discount to closer comparables, while the current share price is US$24.04 against an allowed analyst target reference of US$30.33.
• Consensus narrative supporters argue that revenue growth forecasts of about 17.1% per year alongside expectations for margin improvement could justify a higher multiple. Yet the company’s unprofitable status, and the fact that it is not forecast to become profitable over the next three years, means some investors may question whether a P/S premium to the industry, combined with a DCF fair value that is not available from the data provided here, leaves enough compensation for the risk attached to persistent losses.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for PROCEPT BioRobotics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of promise and pressure in these results, it makes sense to look through the full data and decide where you stand. To weigh the concerns against the potential upside in a structured way, start by checking the 1 key reward and 2 important warning signs.

Explore Alternatives

Ongoing trailing twelve month losses of US$102.5 million, consistent quarterly EPS losses and a P/S premium to the wider industry keep risk and valuation firmly in question.

If that mix of sizeable losses and valuation uncertainty feels uncomfortable, compare it with companies screened for stronger fundamentals and resilience using the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.